+ Site Statistics
+ Search Articles
+ Subscribe to Site Feeds
EurekaMag Most Shared ContentMost Shared
EurekaMag PDF Full Text ContentPDF Full Text
+ PDF Full Text
Request PDF Full TextRequest PDF Full Text
+ Follow Us
Follow on FacebookFollow on Facebook
Follow on TwitterFollow on Twitter
Follow on LinkedInFollow on LinkedIn

+ Translate

Role of RANKL-RANK/osteoprotegerin molecular complex in bone remodeling and its immunopathologic implications

Role of RANKL-RANK/osteoprotegerin molecular complex in bone remodeling and its immunopathologic implications

Indian Journal of Endocrinology and Metabolism 15(3): 175-181

Bone remodeling is a cyclic and continuous physiological process, which ensures the conservation and renewal of the bone matrix. Osteosynthesis of the bone matrix is achieved by osteoblasts and coordinated within this complex machinery of bone remodeling with resorption of extracellular bone matrix performed by osteoclasts. The mismatch between the activities of osteoblasts and osteoclasts has immunopathologic implications associated with either a decrease or increase of bone mass mineral density. The balance of the trimolecular control factor complex composed of osteoprotegerin (OPG), RANKL (osteoprotegerin ligand) and RANK maintains physiologic bone remodeling. This trimolecular complex functions as receptors and ligands and belongs to the superfamily of tumor necrosis factor (TNF). This mini review highlights the complex interplay of the RANKL-RANK/OPG axis and their immunopathologic implications in clinical medicine.

(PDF emailed within 0-6 h: $19.90)

Accession: 055599375

Download citation: RISBibTeXText

PMID: 21897893

DOI: 10.4103/2230-8210.83401

Related references

The role of RANK/RANKL/osteoprotegerin (OPG) triad in cancer-induced bone diseases: physiopathology and clinical implications. Bulletin du Cancer 98(7): 837-846, 2011

RANKL/RANK/OPG molecular complex--control factors in bone remodeling in psoriatic arthritis. Revista Medico-Chirurgicala A Societatii de Medici Si Naturalisti Din Iasi 115(2): 354-360, 2011

Clinical implications of the osteoprotegerin/RANKL/RANK system for bone and vascular diseases. JAMA 292(4): 490-495, 2004

Association between osteoprotegerin (OPG), receptor activator of nuclear factor-kappaB (RANK), and RANK ligand (RANKL) gene polymorphisms and circulating OPG, soluble RANKL levels, and bone mineral density in Korean postmenopausal women. Menopause 14(5): 913-918, 2007

Role of RANKL-RANK/osteoprotegerin pathway in cardiovascular and bone disease associated with HIV infection. Aids Reviews 16(3): 123-133, 2015

The molecular triad OPG/RANK/RANKL: involvement in the orchestration of pathophysiological bone remodeling. Cytokine & Growth Factor Reviews 15(6): 457-475, 2004

Receptor Activator of Nuclear Transcription Factor NF-κB (RANK), Its Ligand RANKL, and Natural Inhibitor of RANKL Osteoprotegerin (OPG) in the Blood Serum of Patients with Primary Bone Tumors. Bulletin of Experimental Biology and Medicine 163(4): 478-481, 2017

Osteoprotegerin/RANK/RANKL axis in cardiac remodeling due to immuno-inflammatory myocardial disease. Experimental and Molecular Pathology 84(3): 213-217, 2008

Theoretical investigation of the role of the RANK-RANKL-OPG system in bone remodeling. Journal of Theoretical Biology 262(2): 306-316, 2010

RANK, RANKL and osteoprotegerin in arthritic bone loss. Brazilian Journal of Medical and Biological Research 38(2): 161-170, 2005

RANK, RANKL and osteoprotegerin in bone biology and disease. Current Reviews in Musculoskeletal Medicine 2(1): 56-64, 2009

The osteoprotegerin/RANK/RANKL system: a bone key to vascular disease. Expert Review of Cardiovascular Therapy 4(6): 801-811, 2006

The osteoprotegerin/RANK/RANKL system: a bone key to vascular disease. Journal of Endocrinological Investigation 32(4 Suppl): 6-9, 2010

Osteoprotegerin/RANK/RANKL axis and atrial remodeling in mitral valvular patients with atrial fibrillation. International Journal of Cardiology 166(3): 702-708, 2014

The role of the osteoprotegerin/RANKL/RANK system in diabetic vascular disease. Current Medicinal Chemistry 18(31): 4813-4819, 2012